Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to the Addex Therapeutics First Quarter twenty twenty six Financial Results and Corporate Update Conference Call and Webcast. At this time, all participants are in listen only mode. After the speakers' presentation, there will be the question and answer session. To ask a question during the session, you need to press 11 on your telephone keypad. You will now hear an automatic message advising your hand is raised. To withdraw your question, please press 11 again. If you wish to ask a question via the webcast, please use the Q and A box available on the webcast link at any time during the live event. Please be advised that today's conference is being recorded. I would now like to hand the conference over to our first speaker today, Tim Dyer, CEO. Please go ahead. Hello, everyone. I would like to thank you all for attending our Q1 twenty twenty six financial results conference call. I am here with Mikhail Kalinichev, our Head of Translational Clients, who will provide an update on our R and D program. I draw your attention to the press release and the financial statements issued earlier today, which are available on our website. I also draw your attention to our disclaimer. We will be making certain forward looking statements that are based on the knowledge we have today. I will start this conference call by giving a quick overview of our recent activities and achievements before reviewing our pipeline. I will then hand over to Misha who will review in more detail our mGAR5 negative allosteric modulator program for brain injury recovery and the GABA B positive modulator program for cough. I will then review our twenty twenty six Q1 financial results. Following that, we will open the call for Q and A. So starting with the ...